Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21836873 | 0.87 | ALDH1A1 (0.65) | ALDH1A1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL11238694 | 0.85 | TSHR (0.61) | ALDH1A1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL4911692 | 0.83 | HSD17B2 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL426745 | 0.83 | MAPT (0.62) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL5372638 | 0.82 | KMT2A (0.64) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL9376320 | 0.82 | NOTUM (0.49) | ALDH1A1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL25606750 | 0.81 | ALDH1A1 (0.51) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL9197504 | 0.81 | MTNR1A (0.46) | ALDH1A1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL23534398 | 0.81 | PDE4B (0.42) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL14966259 | 0.81 | TTR (0.47) | ALDH1A1GABRA1GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695226-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20240366598-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2024214038-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11091482-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190308973-A1 | ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS | ARDELYX, INC. | 2019-10-10 | — | — | US | disclosed |
| EP-2686325-B1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-12-14 | — | — | EP | disclosed |
| CN-103517910-B | Morpholine-spirocyclic piperidine amides as modulators of ion channels | 沃泰克斯药物股份有限公司 | 2016-12-14 | — | — | CN | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8598164-B2 | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2595989-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2013067248-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067248-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-10-18 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2011140425-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140425-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091482-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | FXR1, FXR2, NR1H4 | ALDH1A1 968/4885GABRA1 309/4885GABRG2 844/4885 |
| US-20190308973-A1 | ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS | FXR1, FXR2, NR1H4 | ALDH1A1 968/4885GABRA1 309/4885GABRG2 844/4885 |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | FXR1, FXR2, NR1H4 | ALDH1A1 968/4885GABRA1 309/4885GABRG2 844/4885 |
| US-20240366598-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | ALDH1A1 2995/4885GABRA1 341/4885GABRG2 202/4885 |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | ALDH1A1 1614/4885GABRA1 304/4885GABRG2 502/4885 |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPM5, KCNQ1 | ALDH1A1 1738/4885GABRA1 329/4885GABRG2 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.